首页 > 最新文献

International Journal of Vascular Medicine最新文献

英文 中文
Electronic Cigarette and Atherosclerosis: A Comprehensive Literature Review of Latest Evidences. 电子烟与动脉粥样硬化:最新证据的综合文献综述。
IF 1.3 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2022-08-31 eCollection Date: 2022-01-01 DOI: 10.1155/2022/4136811
Vito Anggarino Damay, Setiawan, Ronny Lesmana, M Rizki Akbar, Antonia Anna Lukito, Vita M Tarawan, Januar W Martha, J Nugroho

Coronary artery diseases (CAD), also known as coronary heart disease (CHD), are the world's leading cause of death. The basis of coronary artery disease is the narrowing of the heart coronary artery lumen due to atherosclerosis. The use of electronic cigarettes has increased significantly over the years. However, harmful effects of electronic cigarettes are still not firm. The aim of this article is to review the impact of electronic cigarette and its role in the pathogenesis of atherosclerosis from recent studies. The results showed that several chemical compounds, such as nicotine, propylene glycol, particulate matters, heavy metals, and flavorings, in electronic cigarette induce atherosclerosis with each molecular mechanism that lead to atherosclerosis progression by formation of ROS, endothelial dysfunction, and inflammation. Further research is still needed to determine the exact mechanism and provide more clinical evidence.

冠状动脉疾病(CAD),也被称为冠心病(CHD),是世界上主要的死亡原因。冠状动脉疾病的基础是由于动脉粥样硬化引起的心脏冠状动脉管腔狭窄。近年来,电子烟的使用显著增加。然而,电子烟的有害影响仍然不确定。本文就电子烟的影响及其在动脉粥样硬化发病机制中的作用进行综述。结果表明,电子烟中的几种化合物,如尼古丁、丙二醇、颗粒物、重金属和调味剂,可诱导动脉粥样硬化,每种分子机制通过ROS的形成、内皮功能障碍和炎症导致动脉粥样硬化进展。还需要进一步的研究来确定确切的机制并提供更多的临床证据。
{"title":"Electronic Cigarette and Atherosclerosis: A Comprehensive Literature Review of Latest Evidences.","authors":"Vito Anggarino Damay,&nbsp;Setiawan,&nbsp;Ronny Lesmana,&nbsp;M Rizki Akbar,&nbsp;Antonia Anna Lukito,&nbsp;Vita M Tarawan,&nbsp;Januar W Martha,&nbsp;J Nugroho","doi":"10.1155/2022/4136811","DOIUrl":"https://doi.org/10.1155/2022/4136811","url":null,"abstract":"<p><p>Coronary artery diseases (CAD), also known as coronary heart disease (CHD), are the world's leading cause of death. The basis of coronary artery disease is the narrowing of the heart coronary artery lumen due to atherosclerosis. The use of electronic cigarettes has increased significantly over the years. However, harmful effects of electronic cigarettes are still not firm. The aim of this article is to review the impact of electronic cigarette and its role in the pathogenesis of atherosclerosis from recent studies. The results showed that several chemical compounds, such as nicotine, propylene glycol, particulate matters, heavy metals, and flavorings, in electronic cigarette induce atherosclerosis with each molecular mechanism that lead to atherosclerosis progression by formation of ROS, endothelial dysfunction, and inflammation. Further research is still needed to determine the exact mechanism and provide more clinical evidence.</p>","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":"2022 ","pages":"4136811"},"PeriodicalIF":1.3,"publicationDate":"2022-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9453087/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33461494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Potential Reduction in Adverse Events and Cost with Novel Anticoagulants among Patients with Acute Limb Ischemia 新型抗凝剂可能降低急性肢体缺血患者的不良事件和费用
IF 1.3 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2022-06-07 DOI: 10.1155/2022/3786815
S. Freeman, Piper C. M. Williams, A. Barón, M. Plomondon, Stephen W. Waldo
Background Acute limb ischemia (ALI) is associated with significant morbidity and mortality. Novel anticoagulants reduce adverse events among patients with peripheral artery disease, though the potential effect of these therapies is unclear in patients with ALI. The present study thus sought to evaluate the potential clinical benefit of universal application of novel anticoagulants to a high-risk population of patients with ALI. Methods In this retrospective cohort study, we identified patients diagnosed with ALI in the Veterans Affairs Healthcare System between 2015 and 2016. We then calculated the incidence of adverse cardiovascular events (death/stroke/myocardial infarction/amputation/repeat intervention) as if they were treated with rivaroxaban using published data. Further, we calculated the cost to treat a Veteran diagnosed with one of these outcomes, and the potential savings had patients been universally treated with novel anticoagulants. Results We identified 286 patients that presented with lower extremity ALI and were not treated with anticoagulation. Potential treatment of these patients with rivaroxaban resulted in significantly fewer adverse events, with an 11.9% reduction in cases at 21 months (95% CI: 5.5-17.8%) and a 13.4% reduction in cases at 47 months (95% CI: 5.6-20.5%). This corresponded to significant decreases in healthcare spending for patients with ALI who were treated with rivaroxaban. Conclusions Among patients with ALI, treatment with rivaroxaban could result in a significant reduction in adverse cardiovascular events. The reduction in events would in turn lead to significant decreases in healthcare spending for this population.
背景:急性肢体缺血(ALI)与显著的发病率和死亡率相关。新型抗凝剂可减少外周动脉疾病患者的不良事件,尽管这些疗法对ALI患者的潜在影响尚不清楚。因此,本研究旨在评估在ALI高危人群中普遍应用新型抗凝剂的潜在临床益处。方法在这项回顾性队列研究中,我们确定了2015年至2016年在退伍军人事务医疗保健系统中诊断为ALI的患者。然后,我们计算不良心血管事件(死亡/中风/心肌梗死/截肢/重复干预)的发生率,就像使用利伐沙班治疗一样。此外,我们计算了治疗被诊断为这些结果之一的退伍军人的费用,以及如果患者普遍使用新型抗凝剂治疗,可能节省的费用。结果286例下肢ALI患者未接受抗凝治疗。利伐沙班对这些患者的潜在治疗导致不良事件显著减少,21个月时病例减少11.9% (95% CI: 5.5-17.8%), 47个月时病例减少13.4% (95% CI: 5.6-20.5%)。这与接受利伐沙班治疗的ALI患者的医疗支出显著降低相对应。结论:在ALI患者中,利伐沙班治疗可显著减少不良心血管事件。事件的减少反过来又会导致这一人群的医疗支出大幅减少。
{"title":"Potential Reduction in Adverse Events and Cost with Novel Anticoagulants among Patients with Acute Limb Ischemia","authors":"S. Freeman, Piper C. M. Williams, A. Barón, M. Plomondon, Stephen W. Waldo","doi":"10.1155/2022/3786815","DOIUrl":"https://doi.org/10.1155/2022/3786815","url":null,"abstract":"Background Acute limb ischemia (ALI) is associated with significant morbidity and mortality. Novel anticoagulants reduce adverse events among patients with peripheral artery disease, though the potential effect of these therapies is unclear in patients with ALI. The present study thus sought to evaluate the potential clinical benefit of universal application of novel anticoagulants to a high-risk population of patients with ALI. Methods In this retrospective cohort study, we identified patients diagnosed with ALI in the Veterans Affairs Healthcare System between 2015 and 2016. We then calculated the incidence of adverse cardiovascular events (death/stroke/myocardial infarction/amputation/repeat intervention) as if they were treated with rivaroxaban using published data. Further, we calculated the cost to treat a Veteran diagnosed with one of these outcomes, and the potential savings had patients been universally treated with novel anticoagulants. Results We identified 286 patients that presented with lower extremity ALI and were not treated with anticoagulation. Potential treatment of these patients with rivaroxaban resulted in significantly fewer adverse events, with an 11.9% reduction in cases at 21 months (95% CI: 5.5-17.8%) and a 13.4% reduction in cases at 47 months (95% CI: 5.6-20.5%). This corresponded to significant decreases in healthcare spending for patients with ALI who were treated with rivaroxaban. Conclusions Among patients with ALI, treatment with rivaroxaban could result in a significant reduction in adverse cardiovascular events. The reduction in events would in turn lead to significant decreases in healthcare spending for this population.","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":"2022 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48725112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study 中东地区房颤患者一年的临床结果:约旦房颤(JoFib)研究
IF 1.3 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2022-04-13 DOI: 10.1155/2022/4240999
A. Hammoudeh, Yousef Khader, R. Tabbalat, Y. Badaineh, N. Kadri, H. Shawer, E. Al-Mousa, R. Ibdah, Batool A. Shawer, I. Alhaddad
Background Prevention of stroke and systemic embolism (SE) prevention in patients with atrial fibrillation (AF) has radically changed in recent years. Data on contemporary utilization of oral anticoagulants (OACs) and cardiovascular outcome in Middle Eastern patients with AF are needed. Methods The Jordan atrial fibrillation (JoFib) study enrolled consecutive patients with AF in Jordan from May 2019 through October 2020 and were followed up for one year after enrollment. Results Overall, 2020 patients were enrolled. The mean age was 67.9 + 13.0 years. Nonvalvular (NVAF) was diagnosed in 1849 (91.5%) patients. OACs were used in 85.7% of high-risk patients with NVAF (CHA2DS2-VASc score>3 in women, and>2 in men), including direct OACs (DOACs) in 64.1% and vitamin K antagonists (VKA) in 35.9%. Adherence rate to the use of the same OAC agent was 90.6% of patients. One-year cardiovascular (CV) mortality was 7.8%, stroke/SE was 4.5%, and major bleeding events were 2.6%. Independent predictors for all-cause mortality in patients with NVAF were age>75 years, heart failure, major bleeding event, type 2 diabetes mellitus, study enrollment as an in-patient, and coronary heart disease. The use of OACs was associated with lower all-cause mortality. The strongest independent predictors for stroke/SE were high-risk CHA2DS2-VASc score and prior history of stroke. Conclusions This study of Middle Eastern AF patients has reported high adherence to OACs. The use of OACs was associated with a lower risk for all-cause mortality. One-year rates of stroke and major bleeding events were comparable to those reported from other regions in the world.
背景:近年来,房颤(AF)患者的卒中预防和系统性栓塞(SE)预防发生了根本性的变化。需要有关中东房颤患者口服抗凝剂(OACs)的当代使用情况和心血管预后的数据。方法约旦心房颤动(JoFib)研究于2019年5月至2020年10月在约旦招募了连续的AF患者,并在入组后随访一年。结果共纳入2020例患者。平均年龄67.9 + 13.0岁。1849例(91.5%)患者被诊断为非瓣膜性房颤。85.7%的非瓣膜性房颤高危患者(女性CHA2DS2-VASc评分为bbb3,男性为bbb2)使用了OACs,其中直接OACs (DOACs)占64.1%,维生素K拮抗剂(VKA)占35.9%。使用同一种OAC药物的依从率为90.6%。一年心血管(CV)死亡率为7.8%,卒中/SE为4.5%,大出血事件为2.6%。非瓣膜性房颤患者全因死亡率的独立预测因子为年龄0 ~ 75岁、心力衰竭、大出血事件、2型糖尿病、作为住院患者纳入研究和冠心病。使用OACs与较低的全因死亡率相关。卒中/SE最强的独立预测因子是高危CHA2DS2-VASc评分和既往卒中史。结论:这项中东房颤患者的研究报告了OACs的高依从性。OACs的使用与全因死亡风险降低相关。一年的中风和大出血事件发生率与世界其他地区的报告相当。
{"title":"One-Year Clinical Outcome in Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study","authors":"A. Hammoudeh, Yousef Khader, R. Tabbalat, Y. Badaineh, N. Kadri, H. Shawer, E. Al-Mousa, R. Ibdah, Batool A. Shawer, I. Alhaddad","doi":"10.1155/2022/4240999","DOIUrl":"https://doi.org/10.1155/2022/4240999","url":null,"abstract":"Background Prevention of stroke and systemic embolism (SE) prevention in patients with atrial fibrillation (AF) has radically changed in recent years. Data on contemporary utilization of oral anticoagulants (OACs) and cardiovascular outcome in Middle Eastern patients with AF are needed. Methods The Jordan atrial fibrillation (JoFib) study enrolled consecutive patients with AF in Jordan from May 2019 through October 2020 and were followed up for one year after enrollment. Results Overall, 2020 patients were enrolled. The mean age was 67.9 + 13.0 years. Nonvalvular (NVAF) was diagnosed in 1849 (91.5%) patients. OACs were used in 85.7% of high-risk patients with NVAF (CHA2DS2-VASc score>3 in women, and>2 in men), including direct OACs (DOACs) in 64.1% and vitamin K antagonists (VKA) in 35.9%. Adherence rate to the use of the same OAC agent was 90.6% of patients. One-year cardiovascular (CV) mortality was 7.8%, stroke/SE was 4.5%, and major bleeding events were 2.6%. Independent predictors for all-cause mortality in patients with NVAF were age>75 years, heart failure, major bleeding event, type 2 diabetes mellitus, study enrollment as an in-patient, and coronary heart disease. The use of OACs was associated with lower all-cause mortality. The strongest independent predictors for stroke/SE were high-risk CHA2DS2-VASc score and prior history of stroke. Conclusions This study of Middle Eastern AF patients has reported high adherence to OACs. The use of OACs was associated with a lower risk for all-cause mortality. One-year rates of stroke and major bleeding events were comparable to those reported from other regions in the world.","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":"2022 1","pages":""},"PeriodicalIF":1.3,"publicationDate":"2022-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"64777590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
High Frequency of Microvascular Dysfunction in US Outpatient Clinics: A Sign of High Residual Risk? Data from 7,105 Patients. 美国门诊微血管功能障碍的高频率:高残留风险的标志?数据来自7105名患者。
IF 1.3 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2022-01-06 eCollection Date: 2022-01-01 DOI: 10.1155/2022/4224975
Morteza Naghavi, Stanley Kleis, Hirofumi Tanaka, Albert A Yen, Ruoyu Zhuang, Ahmed Gul, Yasamin Naghavi, Ralph Metcalfe

Previous studies have linked peripheral microvascular dysfunction measured by arterial tonometry to high residual risk in on-statin patients. Digital thermal monitoring (DTM) of microvascular function is a new and simplified technique based on fingertip temperature measurements that has been correlated with the burden of atherosclerosis and its risk factors. Here, we report analyses of DTM data from two large US registries: Registry-I (6,084 cases) and Registry-II (1,021 cases) across 49 US outpatient clinics. DTM tests were performed using a VENDYS device during a 5-minute arm-cuff reactive hyperemia. Fingertip temperature falls during cuff inflation and rebounds after deflation. Adjusted maximum temperature rebound was reported as vascular reactivity index (VRI). VRI distributions were similar in both registries, with mean ± SD of 1.58 ± 0.53 in Registry-I and 1.52 ± 0.43 in Registry-II. In the combined dataset, only 18% had optimal VRI (≥2.0) and 82% were either poor (<1.0) or intermediate (1.0-2.0). Women had slightly higher VRI than men (1.62 ± 0.56 vs. 1.54 ± 0.47, p < 0.001). VRI was inversely but mildly correlated with age (r = -0.19, p < 0.001). Suboptimal VRI was found in 72% of patients <50 years, 82% of 50-70 years, and 86% of ≥70 years. Blood pressure was not correlated with VRI. In this largest registry of peripheral microvascular function measurements, suboptimal scores were highly frequent among on-treatment patients, possibly suggesting a significant residual risk. Prospective studies are warranted to validate microvascular dysfunction as an indicator of residual risk.

先前的研究已经将动脉血压计测量的外周微血管功能障碍与服用他汀类药物患者的高残留风险联系起来。微血管功能数字热监测(DTM)是一种基于指尖温度测量的新型简化技术,与动脉粥样硬化负担及其危险因素相关。在这里,我们报告了来自美国两个大型登记处的DTM数据的分析:登记处- i(6084例)和登记处- ii(1021例),横跨49个美国门诊诊所。在5分钟的臂袖反应性充血期间,使用VENDYS设备进行DTM测试。袖口膨胀时指尖温度下降,收缩后又反弹。调整后的最高温度回弹作为血管反应性指数(VRI)。两个注册中心的VRI分布相似,注册中心i的平均±SD为1.58±0.53,注册中心ii的平均±SD为1.52±0.43。在合并的数据集中,只有18%的VRI达到最佳(≥2.0),82%的VRI较差(p < 0.001)。VRI与年龄呈负相关但轻度相关(r = -0.19, p < 0.001)。72%的患者VRI不理想
{"title":"High Frequency of Microvascular Dysfunction in US Outpatient Clinics: A Sign of High Residual Risk? Data from 7,105 Patients.","authors":"Morteza Naghavi,&nbsp;Stanley Kleis,&nbsp;Hirofumi Tanaka,&nbsp;Albert A Yen,&nbsp;Ruoyu Zhuang,&nbsp;Ahmed Gul,&nbsp;Yasamin Naghavi,&nbsp;Ralph Metcalfe","doi":"10.1155/2022/4224975","DOIUrl":"https://doi.org/10.1155/2022/4224975","url":null,"abstract":"<p><p>Previous studies have linked peripheral microvascular dysfunction measured by arterial tonometry to high residual risk in on-statin patients. Digital thermal monitoring (DTM) of microvascular function is a new and simplified technique based on fingertip temperature measurements that has been correlated with the burden of atherosclerosis and its risk factors. Here, we report analyses of DTM data from two large US registries: Registry-I (6,084 cases) and Registry-II (1,021 cases) across 49 US outpatient clinics. DTM tests were performed using a VENDYS device during a 5-minute arm-cuff reactive hyperemia. Fingertip temperature falls during cuff inflation and rebounds after deflation. Adjusted maximum temperature rebound was reported as vascular reactivity index (VRI). VRI distributions were similar in both registries, with mean ± SD of 1.58 ± 0.53 in Registry-I and 1.52 ± 0.43 in Registry-II. In the combined dataset, only 18% had optimal VRI (≥2.0) and 82% were either poor (<1.0) or intermediate (1.0-2.0). Women had slightly higher VRI than men (1.62 ± 0.56 vs. 1.54 ± 0.47, <i>p</i> < 0.001). VRI was inversely but mildly correlated with age (<i>r</i> = -0.19, <i>p</i> < 0.001). Suboptimal VRI was found in 72% of patients <50 years, 82% of 50-70 years, and 86% of ≥70 years. Blood pressure was not correlated with VRI. In this largest registry of peripheral microvascular function measurements, suboptimal scores were highly frequent among on-treatment patients, possibly suggesting a significant residual risk. Prospective studies are warranted to validate microvascular dysfunction as an indicator of residual risk.</p>","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":"2022 ","pages":"4224975"},"PeriodicalIF":1.3,"publicationDate":"2022-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758294/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39939543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Healthcare Practitioners' Knowledge of Lymphedema. 医疗保健从业人员的淋巴水肿知识。
IF 1.3 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2021-12-31 eCollection Date: 2021-01-01 DOI: 10.1155/2021/3806150
Hossein Yarmohammadi, Amirhossein Rooddehghan, Masood Soltanipur, Amirabbas Sarafraz, Seyed Fatah Mahdavi Anari

Objectives: Lymphedema is neglected in medical education, and a review on healthcare practitioners' (HCPs) knowledge is necessary to shed light on gaps and to provide evidence for establishing educational programs on lymphedema.

Methods: This systematic review was performed based on the PRISMA guideline in PubMed, Scopus, Web of Science, and Google Scholar databases. There was no limitation on the type of lymphedema or HCPs. The quality assessment was performed based on QATSDD. Data regarding study characteristics, questionnaire context, and findings of the study were summarized from each article.

Results: After the screening, 16 articles were included that 12 were cross-sectional, two were qualitative, and two were interventional pilot studies. Breast cancer and other cancer-related lymphedema, lymphatic filariasis, and podoconiosis were included, and the majority of articles were focused on primary HCPs. The overall knowledge was low and average in five and 11 articles, respectively, and prior education was a significant factor related to higher knowledge of lymphedema in two studies.

Conclusion: Structured education of lymphedema is needed to increase the knowledge of HCPs and to enhance their collaboration in multidisciplinary care teams. Improvement of HCPs' knowledge may lead to better outcomes of lymphedema patients' management which are neglected.

目的:淋巴水肿在医学教育中被忽视,对医疗从业者(HCPs)知识的回顾是必要的,以阐明差距,并为建立淋巴水肿教育计划提供证据。方法:本系统综述基于PubMed、Scopus、Web of Science和Google Scholar数据库中的PRISMA指南进行。对淋巴水肿或HCPs的类型没有限制。基于QATSDD进行质量评价。每篇文章总结了有关研究特征、问卷背景和研究结果的数据。结果:筛选后,纳入16篇文章,其中12篇为横断面研究,2篇为定性研究,2篇为介入性先导研究。乳腺癌和其他与癌症相关的淋巴水肿、淋巴丝虫病和足癣病也被纳入其中,大多数文章都集中在原发性HCPs上。5篇和11篇文章的总体知识水平分别为低水平和中等水平,两篇研究的教育背景是提高淋巴水肿知识水平的重要因素。结论:需要对淋巴水肿进行结构化的教育,以增加医护人员的知识,并加强他们在多学科护理团队中的合作。提高医护人员的知识可能会改善被忽视的淋巴水肿患者的治疗效果。
{"title":"Healthcare Practitioners' Knowledge of Lymphedema.","authors":"Hossein Yarmohammadi,&nbsp;Amirhossein Rooddehghan,&nbsp;Masood Soltanipur,&nbsp;Amirabbas Sarafraz,&nbsp;Seyed Fatah Mahdavi Anari","doi":"10.1155/2021/3806150","DOIUrl":"https://doi.org/10.1155/2021/3806150","url":null,"abstract":"<p><strong>Objectives: </strong>Lymphedema is neglected in medical education, and a review on healthcare practitioners' (HCPs) knowledge is necessary to shed light on gaps and to provide evidence for establishing educational programs on lymphedema.</p><p><strong>Methods: </strong>This systematic review was performed based on the PRISMA guideline in PubMed, Scopus, Web of Science, and Google Scholar databases. There was no limitation on the type of lymphedema or HCPs. The quality assessment was performed based on QATSDD. Data regarding study characteristics, questionnaire context, and findings of the study were summarized from each article.</p><p><strong>Results: </strong>After the screening, 16 articles were included that 12 were cross-sectional, two were qualitative, and two were interventional pilot studies. Breast cancer and other cancer-related lymphedema, lymphatic filariasis, and podoconiosis were included, and the majority of articles were focused on primary HCPs. The overall knowledge was low and average in five and 11 articles, respectively, and prior education was a significant factor related to higher knowledge of lymphedema in two studies.</p><p><strong>Conclusion: </strong>Structured education of lymphedema is needed to increase the knowledge of HCPs and to enhance their collaboration in multidisciplinary care teams. Improvement of HCPs' knowledge may lead to better outcomes of lymphedema patients' management which are neglected.</p>","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":"2021 ","pages":"3806150"},"PeriodicalIF":1.3,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39800928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
A Review of Risk Factors and Predictors for Hemorrhagic Transformation in Patients with Acute Ischemic Stroke. 急性缺血性脑卒中患者出血转化的危险因素及预测因素综述。
IF 1.3 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2021-12-06 eCollection Date: 2021-01-01 DOI: 10.1155/2021/4244267
Sneha E Thomas, Noorine Plumber, Priyanka Venkatapathappa, Vasavi Gorantla

Acute ischemic strokes (AIS) and hemorrhagic strokes lead to disabling neuropsychiatric and cognitive deficits. A serious and fatal complication of AIS is the occurrence of hemorrhagic transformation (HT). HT is cerebral bleeding that occurs after an ischemic event in the infarcted areas. This review summarises how specific risk factors such as demographic factors like age, gender, and race/ethnicity, comorbidities including essential hypertension, atrial fibrillation, diabetes mellitus, congestive heart failure, and ischemic heart disease along with predictors like higher NIHSS score, larger infarction size, cardioembolic strokes, systolic blood pressure/pulse pressure variability, higher plasma glucose levels, and higher body temperature during ischemic event, lower low-density lipoprotein and total cholesterol, early ischemic changes on imaging modalities, and some rare causes make an individual more susceptible to developing HT. We also discuss few other risk factors such as the role of blood-brain barrier, increased arterial stiffness, and globulin levels in patients postreperfusion using thrombolysis and mechanical thrombectomy. In addition, we discuss the implications of dual antiplatelet therapy and the length of treatment in reference to the incidence of developing HT. Current research into inflammatory mediators and biomarkers such as Cyclooxygenase-2, matrix metalloproteinases, and soluble ST2 and their potential role as treatment options for HT is also briefly discussed. Finally, this review calls for more research into use of dual antiplatelet and the timing of antiplatelet and anticoagulant use in reference to hemorrhagic transformation.

急性缺血性中风(AIS)和出血性中风导致致残性神经精神和认知缺陷。出血性转化(HT)是AIS的一个严重和致命的并发症。HT是在梗死区域发生缺血事件后发生的脑出血。这篇综述总结了特定的危险因素,如人口统计学因素,如年龄、性别和种族/民族,合并症,包括原发性高血压、心房颤动、糖尿病、充血性心力衰竭和缺血性心脏病,以及预测因素,如较高的NIHSS评分、较大的梗死面积、心栓性中风、收缩压/脉压变异性、较高的血糖水平和缺血性事件期间较高的体温,较低的低密度脂蛋白和总胆固醇,早期缺血性影像学改变,以及一些罕见的原因使个体更容易发生HT。我们还讨论了其他一些危险因素,如血脑屏障的作用,动脉僵硬度增加,以及使用溶栓和机械取栓的患者灌注后的球蛋白水平。此外,我们讨论了双重抗血小板治疗的意义和治疗时间的长短,参考发生HT的发生率。本文还简要讨论了炎症介质和生物标志物(如环氧化酶-2、基质金属蛋白酶和可溶性ST2)的研究现状及其作为HT治疗方案的潜在作用。最后,这篇综述呼吁对双重抗血小板药物的使用以及抗血小板和抗凝药物的使用时机进行更多的研究,以参考出血转化。
{"title":"A Review of Risk Factors and Predictors for Hemorrhagic Transformation in Patients with Acute Ischemic Stroke.","authors":"Sneha E Thomas,&nbsp;Noorine Plumber,&nbsp;Priyanka Venkatapathappa,&nbsp;Vasavi Gorantla","doi":"10.1155/2021/4244267","DOIUrl":"https://doi.org/10.1155/2021/4244267","url":null,"abstract":"<p><p>Acute ischemic strokes (AIS) and hemorrhagic strokes lead to disabling neuropsychiatric and cognitive deficits. A serious and fatal complication of AIS is the occurrence of hemorrhagic transformation (HT). HT is cerebral bleeding that occurs after an ischemic event in the infarcted areas. This review summarises how specific risk factors such as demographic factors like age, gender, and race/ethnicity, comorbidities including essential hypertension, atrial fibrillation, diabetes mellitus, congestive heart failure, and ischemic heart disease along with predictors like higher NIHSS score, larger infarction size, cardioembolic strokes, systolic blood pressure/pulse pressure variability, higher plasma glucose levels, and higher body temperature during ischemic event, lower low-density lipoprotein and total cholesterol, early ischemic changes on imaging modalities, and some rare causes make an individual more susceptible to developing HT. We also discuss few other risk factors such as the role of blood-brain barrier, increased arterial stiffness, and globulin levels in patients postreperfusion using thrombolysis and mechanical thrombectomy. In addition, we discuss the implications of dual antiplatelet therapy and the length of treatment in reference to the incidence of developing HT. Current research into inflammatory mediators and biomarkers such as Cyclooxygenase-2, matrix metalloproteinases, and soluble ST2 and their potential role as treatment options for HT is also briefly discussed. Finally, this review calls for more research into use of dual antiplatelet and the timing of antiplatelet and anticoagulant use in reference to hemorrhagic transformation.</p>","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":"2021 ","pages":"4244267"},"PeriodicalIF":1.3,"publicationDate":"2021-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8668348/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39730394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Segmental Arterial Mediolysis: A Multiguised Vasospastic Arteriopathy with Collateral Mesangial Cell Hyperplasia and Cardiac Toxicity Generated by Norepinephrine and Hyperdense Adrenoceptors Alone or by Crosstalk with Other Pressor Agents. 节段性动脉中膜溶解:单用去甲肾上腺素和高密度肾上腺素或与其他压力药物串扰引起的伴侧系膜细胞增生和心脏毒性的多形性血管痉挛动脉病变。
IF 1.3 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2021-11-23 eCollection Date: 2021-01-01 DOI: 10.1155/2021/2046566
Richard E Slavin

Segmental arterial mediolysis (SAM), an uncommon vasospastic arteriopathy occurring in the muscular arteries innervated by the peripheral sympathetic nervous system, usually presents with catastrophic abdominal and retroperitoneal hemorrhages in elderly patients. SAM is initiated by the coupling of norepinephrine to plastically derived hyperdense foci of alpha-1 adrenergic receptors on the sarcolemma of arterial muscle. This ligand is created by stimuli signaled by iatrogenic sympathomimetic agonists, some beta-2 agonists, or an excessive release of adrenal catecholamines. Coupling of this ligand with cytoplasmic heterotrimeric Gq protein excessively signals a cascade of biochemical events generating two principal lesions of injurious-phase SAM-the shearing of the outer media from the adventitia and an overload of cytoplasmic calcium ions toxic to mitochondria causing mediolysis and/or apoptosis. The massive hemorrhages are caused by ruptured gap aneurysms created by the transmedial loss of the medial muscle. A norepinephrine-directed reparative response rapidly develops either resolving angiographic injurious lesions or creating a body of vascular disorders, the new guises of SAM with ischemic clinical profiles. These present in the epicardial, vertebral, intestinal, and retroperitoneal arteries, often in younger females as fibromuscular dysplasia, dissecting hematomas, and persistent aneurysms. Norepinephrine can crosstalk with other pressor agents to create SAM lesions-serotonin with idiopathic pulmonary hypertension and persistent pulmonary hypertension in the newborn, histamine in spontaneous coronary artery dissections with eosinophilia, and endothelin-1 in a field effect generated by SAM that creates venous fibromuscular dysplasia. Norepinephrine also participates in the collateral development of mesangial hyperplasia with focal segmental glomerulosclerosis and myocardial mediolysis and apoptosis in subjects with markedly elevated heart rates. Conclusion. Norepinephrine coupling with plastically elevated alpha-1 adrenoceptor or other pressor agents generates SAM, a histologically recognizable vasospastic arteriopathy, that with repair is transformed into several different standardized arterial diseases that alter SAM's clinical profile from a hemorrhagic to an ischemic disorder.

节段性动脉介质溶解(SAM)是一种罕见的血管痉挛性动脉病,发生在由外周交感神经系统支配的肌肉动脉中,通常表现为老年患者腹部和腹膜后出血。SAM是由去甲肾上腺素与动脉肌膜上α -1肾上腺素能受体的塑性衍生的高密度灶偶联引起的。这种配体是由医源性拟交感神经激动剂、某些β -2激动剂或肾上腺儿茶酚胺过度释放的刺激信号产生的。这种配体与细胞质异三聚体Gq蛋白的偶联过度地发出了一系列生化事件的信号,产生了两种主要的损伤期sam损伤——外膜剪切和细胞质钙离子过载,对线粒体有毒,导致介质溶解和/或凋亡。大出血是由内侧肌肉的损失造成的间隙动脉瘤破裂引起的。去甲肾上腺素导向的修复反应迅速发展,要么解决血管造影损伤病变,要么产生血管疾病,这是具有缺血性临床特征的SAM的新形式。常见于心外膜动脉、椎动脉、肠动脉和腹膜后动脉,常见于年轻女性,表现为纤维肌肉发育不良、解剖性血肿和持续性动脉瘤。去甲肾上腺素可与其他降压药物相互作用产生SAM损伤——5 -羟色胺与特发性肺动脉高压和新生儿持续性肺动脉高压有关,组胺与自发性冠状动脉夹层伴嗜酸性粒细胞增多有关,内皮素-1与SAM产生的场效应有关,可造成静脉纤维肌肉发育不良。在心率明显升高的受试者中,去甲肾上腺素也参与系膜增生伴局灶节段性肾小球硬化、心肌介质溶解和细胞凋亡的侧枝发展。结论。去甲肾上腺素与可塑性升高的α -1肾上腺素受体或其他加压剂偶联产生SAM,这是一种组织学上可识别的血管痉挛性动脉疾病,随着修复,SAM转变为几种不同的标准化动脉疾病,将SAM的临床特征从出血性疾病转变为缺血性疾病。
{"title":"Segmental Arterial Mediolysis: A Multiguised Vasospastic Arteriopathy with Collateral Mesangial Cell Hyperplasia and Cardiac Toxicity Generated by Norepinephrine and Hyperdense Adrenoceptors Alone or by Crosstalk with Other Pressor Agents.","authors":"Richard E Slavin","doi":"10.1155/2021/2046566","DOIUrl":"https://doi.org/10.1155/2021/2046566","url":null,"abstract":"<p><p>Segmental arterial mediolysis (SAM), an uncommon vasospastic arteriopathy occurring in the muscular arteries innervated by the peripheral sympathetic nervous system, usually presents with catastrophic abdominal and retroperitoneal hemorrhages in elderly patients. SAM is initiated by the coupling of norepinephrine to plastically derived hyperdense foci of alpha-1 adrenergic receptors on the sarcolemma of arterial muscle. This ligand is created by stimuli signaled by iatrogenic sympathomimetic agonists, some beta-2 agonists, or an excessive release of adrenal catecholamines. Coupling of this ligand with cytoplasmic heterotrimeric Gq protein excessively signals a cascade of biochemical events generating two principal lesions of injurious-phase SAM-the shearing of the outer media from the adventitia and an overload of cytoplasmic calcium ions toxic to mitochondria causing mediolysis and/or apoptosis. The massive hemorrhages are caused by ruptured gap aneurysms created by the transmedial loss of the medial muscle. A norepinephrine-directed reparative response rapidly develops either resolving angiographic injurious lesions or creating a body of vascular disorders, the new guises of SAM with ischemic clinical profiles. These present in the epicardial, vertebral, intestinal, and retroperitoneal arteries, often in younger females as fibromuscular dysplasia, dissecting hematomas, and persistent aneurysms. Norepinephrine can crosstalk with other pressor agents to create SAM lesions-serotonin with idiopathic pulmonary hypertension and persistent pulmonary hypertension in the newborn, histamine in spontaneous coronary artery dissections with eosinophilia, and endothelin-1 in a field effect generated by SAM that creates venous fibromuscular dysplasia. Norepinephrine also participates in the collateral development of mesangial hyperplasia with focal segmental glomerulosclerosis and myocardial mediolysis and apoptosis in subjects with markedly elevated heart rates. <i>Conclusion</i>. Norepinephrine coupling with plastically elevated alpha-1 adrenoceptor or other pressor agents generates SAM, a histologically recognizable vasospastic arteriopathy, that with repair is transformed into several different standardized arterial diseases that alter SAM's clinical profile from a hemorrhagic to an ischemic disorder.</p>","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":"2021 ","pages":"2046566"},"PeriodicalIF":1.3,"publicationDate":"2021-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646181/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39703875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Use of the AFX Stent Graft in Patients with Extremely Narrow Aortic Bifurcation: A Multicenter Retrospective Study. AFX支架在极窄主动脉分叉患者中的应用:一项多中心回顾性研究
IF 1.3 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2021-10-04 eCollection Date: 2021-01-01 DOI: 10.1155/2021/7439173
M U Wagenhäuser, N Floros, E Nikitina, J Mulorz, K M Balzer, S Goulas, M Petrich, P Dueppers, F Simon, H Schelzig, A Oberhuber

Introduction: This study analyzed the patient outcomes following endovascular aortic aneurysm repair (EVAR) for infrarenal aortic pathologies with very narrow aortic bifurcations using the AFX stent graft.

Methods: The data was retrieved from the archived medical records of 35 patients treated for abdominal aortic aneurysm (AAA) (48.6%) or penetrating aortic ulcer (PAU) (51.4%) with very narrow aortic bifurcation between January 2013 and May 2020. Patient survival, freedom from endoleak (EL), and limb occlusion were estimated applying the Kaplan-Meier method.

Results: The mean follow-up time was 20.4 ± 22.8 months. The mean aortic bifurcation diameter was 15.8 ± 2.2 mm. Technical success was 100%, and no procedure-related deaths occurred. Two type II ELs occurred within 30-day follow-up. We observed one common iliac artery stenosis at four months and one type III EL at 54 months in the same patient, both of which required re-intervention. Overall patient survival was 95 ± 5% (AAA: 100%; PAU: 89 ± 10%), freedom from limb occlusion was 94 ± 5% (AAA: 91 ± 9%; PAU: 100%), freedom from type II EL was 94 ± 4% (AAA: 88 ± 8%; PAU: 100%), and freedom from EL type III was 83 ± 15% (AAA: 80 ± 18%; PAU: 100%) at the end of the follow-up period.

Conclusions: Very narrow aortic bifurcations may predispose patients to procedure-related complications following EVAR. Our results suggest a safe use of the AFX stent graft in such scenarios. The overall short- and long-term procedure-related patient outcomes are satisfying albeit they may seem superior for PAU when compared to AAA.

简介:本研究分析了使用AFX支架对非常狭窄的肾下主动脉病变进行血管内动脉瘤修复(EVAR)后的患者预后。方法:收集2013年1月至2020年5月收治的35例腹主动脉瘤(AAA)(48.6%)或穿透性主动脉溃疡(PAU)(51.4%)患者的病历资料,其中主动脉分叉极窄。应用Kaplan-Meier方法估计患者的生存、无内皮渗漏(EL)和肢体闭塞。结果:平均随访时间为20.4±22.8个月。平均主动脉分叉直径15.8±2.2 mm。技术成功率为100%,无手术相关死亡发生。随访30天内发生2例II型el。在同一例患者中,我们在4个月时观察到1例常见髂动脉狭窄,在54个月时观察到1例III型EL,两者都需要再次干预。患者总生存率为95±5% (AAA: 100%;PAU: 89±10%),肢体无闭塞性94±5% (AAA: 91±9%;PAU: 100%), II型EL的自由度为94±4% (AAA: 88±8%;PAU: 100%), III型EL自由度为83±15% (AAA: 80±18%;PAU: 100%)在随访期结束时。结论:非常窄的主动脉分叉可能使患者在EVAR后易发生手术相关并发症。我们的结果表明在这种情况下使用AFX支架是安全的。尽管与AAA相比,PAU的总体短期和长期手术相关的患者结果似乎更令人满意。
{"title":"Use of the AFX Stent Graft in Patients with Extremely Narrow Aortic Bifurcation: A Multicenter Retrospective Study.","authors":"M U Wagenhäuser,&nbsp;N Floros,&nbsp;E Nikitina,&nbsp;J Mulorz,&nbsp;K M Balzer,&nbsp;S Goulas,&nbsp;M Petrich,&nbsp;P Dueppers,&nbsp;F Simon,&nbsp;H Schelzig,&nbsp;A Oberhuber","doi":"10.1155/2021/7439173","DOIUrl":"https://doi.org/10.1155/2021/7439173","url":null,"abstract":"<p><strong>Introduction: </strong>This study analyzed the patient outcomes following endovascular aortic aneurysm repair (EVAR) for infrarenal aortic pathologies with very narrow aortic bifurcations using the AFX stent graft.</p><p><strong>Methods: </strong>The data was retrieved from the archived medical records of 35 patients treated for abdominal aortic aneurysm (AAA) (48.6%) or penetrating aortic ulcer (PAU) (51.4%) with very narrow aortic bifurcation between January 2013 and May 2020. Patient survival, freedom from endoleak (EL), and limb occlusion were estimated applying the Kaplan-Meier method.</p><p><strong>Results: </strong>The mean follow-up time was 20.4 ± 22.8 months. The mean aortic bifurcation diameter was 15.8 ± 2.2 mm. Technical success was 100%, and no procedure-related deaths occurred. Two type II ELs occurred within 30-day follow-up. We observed one common iliac artery stenosis at four months and one type III EL at 54 months in the same patient, both of which required re-intervention. Overall patient survival was 95 ± 5% (AAA: 100%; PAU: 89 ± 10%), freedom from limb occlusion was 94 ± 5% (AAA: 91 ± 9%; PAU: 100%), freedom from type II EL was 94 ± 4% (AAA: 88 ± 8%; PAU: 100%), and freedom from EL type III was 83 ± 15% (AAA: 80 ± 18%; PAU: 100%) at the end of the follow-up period.</p><p><strong>Conclusions: </strong>Very narrow aortic bifurcations may predispose patients to procedure-related complications following EVAR. Our results suggest a safe use of the AFX stent graft in such scenarios. The overall short- and long-term procedure-related patient outcomes are satisfying albeit they may seem superior for PAU when compared to AAA.</p>","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":"2021 ","pages":"7439173"},"PeriodicalIF":1.3,"publicationDate":"2021-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39515698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Retrograde Popliteal Access for Challenging Superficial Femoral Artery Occlusion. 腘窝逆行入路治疗股浅动脉闭塞。
IF 1.3 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2021-05-17 eCollection Date: 2021-01-01 DOI: 10.1155/2021/8833025
Georges Ibrahim, Sami Nabhani, Michel Feghaly

Retrograde popliteal access has long been established as an alternative to the antegrade approach to occlusive lesions in the superficial femoral artery (SFA). However, early reports with high complication rates (dissection, hematomas, aneurysms, and arteriovenous shunts at the puncture site) reduced enthusiasm for this technique. In recent years, with the development of thinner sheaths and low profile angioplasty devices, retrograde popliteal access has resurfaced as a viable technique, mostly in combination with or after failure of the more classical antegrade approach. In this retrospective study, we will report the safety and efficacy of the retrograde popliteal approach in the treatment of superficial femoral artery chronic total occlusions, in 13 consecutive patients between January 2017 and January 2021. The results showed 100% successful puncture of the popliteal artery and 100% successful recanalization and stenting of the superficial femoral artery with a total of 2 complications related to the puncture site and zero periprocedural mortality. In conclusion, the retrograde popliteal approach appears to be an effective and safe alternative to the common SFA complete total occlusion (CTO) treatment approach.

长期以来,逆行腘动脉入路一直被认为是治疗股浅动脉(SFA)闭塞性病变的一种替代方法。然而,早期报道的高并发症发生率(夹层、血肿、动脉瘤和穿刺部位动静脉分流)降低了对该技术的热情。近年来,随着更薄的血管鞘和低轮廓血管成形术设备的发展,逆行腘窝入路重新成为一种可行的技术,主要是与更经典的顺行入路联合或在失败后。在这项回顾性研究中,我们将在2017年1月至2021年1月期间连续13例患者中报告逆行腘窝入路治疗股浅动脉慢性全闭塞的安全性和有效性。结果显示腘动脉穿刺100%成功,股浅动脉再通和支架置入100%成功,与穿刺部位相关的并发症共2例,术中死亡率为零。总之,逆行腘窝入路似乎是一种有效和安全的替代常见的SFA完全全闭塞(CTO)治疗入路。
{"title":"Retrograde Popliteal Access for Challenging Superficial Femoral Artery Occlusion.","authors":"Georges Ibrahim,&nbsp;Sami Nabhani,&nbsp;Michel Feghaly","doi":"10.1155/2021/8833025","DOIUrl":"https://doi.org/10.1155/2021/8833025","url":null,"abstract":"<p><p>Retrograde popliteal access has long been established as an alternative to the antegrade approach to occlusive lesions in the superficial femoral artery (SFA). However, early reports with high complication rates (dissection, hematomas, aneurysms, and arteriovenous shunts at the puncture site) reduced enthusiasm for this technique. In recent years, with the development of thinner sheaths and low profile angioplasty devices, retrograde popliteal access has resurfaced as a viable technique, mostly in combination with or after failure of the more classical antegrade approach. In this retrospective study, we will report the safety and efficacy of the retrograde popliteal approach in the treatment of superficial femoral artery chronic total occlusions, in 13 consecutive patients between January 2017 and January 2021. The results showed 100% successful puncture of the popliteal artery and 100% successful recanalization and stenting of the superficial femoral artery with a total of 2 complications related to the puncture site and zero periprocedural mortality. In conclusion, the retrograde popliteal approach appears to be an effective and safe alternative to the common SFA complete total occlusion (CTO) treatment approach.</p>","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":"2021 ","pages":"8833025"},"PeriodicalIF":1.3,"publicationDate":"2021-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149250/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39032806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Getting to the Heart of the Matter: Myocardial Injury, Coagulopathy, and Other Potential Cardiovascular Implications of COVID-19. 切入核心问题:COVID-19的心肌损伤、凝血功能障碍和其他潜在心血管影响。
IF 1.3 Q2 PERIPHERAL VASCULAR DISEASE Pub Date : 2021-04-22 eCollection Date: 2021-01-01 DOI: 10.1155/2021/6693895
Aaron Schmid, Marija Petrovic, Kavya Akella, Anisha Pareddy, Sumathilatha Sakthi Velavan

COVID-19 was primarily identified as a respiratory illness, but reports of patients presenting initially with cardiovascular complaints are rapidly emerging. Many patients also develop cardiovascular complications during and after COVID-19 infection. Underlying cardiovascular disease increases the severity of COVID-19 infection; however, it is unclear if COVID-19 increases the risk of or causes cardiovascular complications in patients without preexisting cardiovascular disease. The review is aimed at informing the primary care physicians of the potential cardiovascular complications, especially in patients without underlying cardiovascular disease. A comprehensive literature review was performed on cardiac and vascular complications of COVID-19. The primary cardiac and vascular complications include myocarditis, acute coronary syndrome, myocardial injury, arrhythmia, heart failure, shock, multisystem inflammatory syndrome, venous and arterial thrombotic events, stroke, and coagulopathy. A detailed analysis of the pathogenesis revealed six possible mechanisms: direct cardiac damage, hypoxia-induced injury, inflammation, a dysfunctional endothelial response, coagulopathy, and the catecholamine stress response. Autopsy reports from studies show cardiomegaly, hypertrophy, ventricular dilation, infarction, and fibrosis. A wide range of cardiac and vascular complications should be considered when treating patients with confirmed or suspected COVID-19 infection. Elevated troponin and natriuretic peptides indicate an early cardiac involvement in COVID-19. Continuous monitoring of coagulation by measuring serum D-dimer can potentially prevent vascular complications. A long-term screening protocol to follow-up the patients in the primary care settings is needed to follow-up with the patients who recovered from COVID cardiovascular complications.

COVID-19最初被确定为一种呼吸道疾病,但有关最初以心血管疾病为症状的患者的报告正在迅速出现。许多患者在COVID-19感染期间和之后还会出现心血管并发症。潜在心血管疾病增加了COVID-19感染的严重程度;然而,目前尚不清楚COVID-19是否会增加无心血管疾病患者的心血管并发症风险或导致心血管并发症。该综述旨在告知初级保健医生潜在的心血管并发症,特别是在没有潜在心血管疾病的患者中。我们对COVID-19的心脏和血管并发症进行了全面的文献综述。主要的心脏和血管并发症包括心肌炎、急性冠状动脉综合征、心肌损伤、心律失常、心力衰竭、休克、多系统炎症综合征、静脉和动脉血栓形成事件、中风和凝血功能障碍。对其发病机制的详细分析揭示了六种可能的机制:直接心脏损伤、缺氧引起的损伤、炎症、内皮反应功能障碍、凝血功能障碍和儿茶酚胺应激反应。尸检报告显示心脏肥大、肥厚、心室扩张、梗塞和纤维化。在治疗确诊或疑似COVID-19感染的患者时,应考虑广泛的心血管并发症。肌钙蛋白和利钠肽升高表明COVID-19患者早期心脏受累。通过测量血清d -二聚体持续监测凝血可以潜在地预防血管并发症。需要制定长期筛查方案,在初级保健机构对COVID - 19心血管并发症康复患者进行随访。
{"title":"Getting to the Heart of the Matter: Myocardial Injury, Coagulopathy, and Other Potential Cardiovascular Implications of COVID-19.","authors":"Aaron Schmid,&nbsp;Marija Petrovic,&nbsp;Kavya Akella,&nbsp;Anisha Pareddy,&nbsp;Sumathilatha Sakthi Velavan","doi":"10.1155/2021/6693895","DOIUrl":"https://doi.org/10.1155/2021/6693895","url":null,"abstract":"<p><p>COVID-19 was primarily identified as a respiratory illness, but reports of patients presenting initially with cardiovascular complaints are rapidly emerging. Many patients also develop cardiovascular complications during and after COVID-19 infection. Underlying cardiovascular disease increases the severity of COVID-19 infection; however, it is unclear if COVID-19 increases the risk of or causes cardiovascular complications in patients without preexisting cardiovascular disease. The review is aimed at informing the primary care physicians of the potential cardiovascular complications, especially in patients without underlying cardiovascular disease. A comprehensive literature review was performed on cardiac and vascular complications of COVID-19. The primary cardiac and vascular complications include myocarditis, acute coronary syndrome, myocardial injury, arrhythmia, heart failure, shock, multisystem inflammatory syndrome, venous and arterial thrombotic events, stroke, and coagulopathy. A detailed analysis of the pathogenesis revealed six possible mechanisms: direct cardiac damage, hypoxia-induced injury, inflammation, a dysfunctional endothelial response, coagulopathy, and the catecholamine stress response. Autopsy reports from studies show cardiomegaly, hypertrophy, ventricular dilation, infarction, and fibrosis. A wide range of cardiac and vascular complications should be considered when treating patients with confirmed or suspected COVID-19 infection. Elevated troponin and natriuretic peptides indicate an early cardiac involvement in COVID-19. Continuous monitoring of coagulation by measuring serum D-dimer can potentially prevent vascular complications. A long-term screening protocol to follow-up the patients in the primary care settings is needed to follow-up with the patients who recovered from COVID cardiovascular complications.</p>","PeriodicalId":14448,"journal":{"name":"International Journal of Vascular Medicine","volume":"2021 ","pages":"6693895"},"PeriodicalIF":1.3,"publicationDate":"2021-04-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118745/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39018619","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
期刊
International Journal of Vascular Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1